Public Employees Retirement System of Ohio Reduces Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Public Employees Retirement System of Ohio decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,416 shares of the company's stock after selling 4,675 shares during the period. Public Employees Retirement System of Ohio's holdings in IDEXX Laboratories were worth $12,575,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Hantz Financial Services Inc. raised its position in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after acquiring an additional 800 shares in the last quarter. Paragon Capital Management Inc. grew its stake in shares of IDEXX Laboratories by 25.7% in the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock worth $1,579,000 after buying an additional 782 shares during the last quarter. Fiera Capital Corp grew its stake in shares of IDEXX Laboratories by 12.3% in the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock worth $58,377,000 after buying an additional 15,463 shares during the last quarter. Lecap Asset Management Ltd. grew its stake in shares of IDEXX Laboratories by 587.7% in the 4th quarter. Lecap Asset Management Ltd. now owns 5,701 shares of the company's stock worth $2,357,000 after buying an additional 4,872 shares during the last quarter. Finally, Blue Zone Wealth Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $3,958,000. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

IDXX has been the topic of several recent analyst reports. Morgan Stanley increased their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Stifel Nicolaus raised their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday, May 19th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Finally, Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Stock Down 1.0%

Shares of IDXX stock traded down $5.18 during trading hours on Friday, reaching $510.38. 143,454 shares of the company's stock were exchanged, compared to its average volume of 648,910. The stock's 50 day moving average is $447.90 and its 200-day moving average is $436.67. The company has a market cap of $41.05 billion, a price-to-earnings ratio of 47.83, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $530.60.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.71 earnings per share. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In other news, Director M Anne Szostak sold 1,046 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total transaction of $537,372.04. Following the sale, the director now directly owns 262 shares of the company's stock, valued at $134,599.88. The trade was a 79.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.